BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Eptinezumab (Vyepti) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Eptinezumab (Vyepti)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04965675-10396@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20270326
DTEND;VALUE=DATE:20270327
SUMMARY:Eptinezumab (Vyepti): Phase 3 readout est. (NCT04965675)
DESCRIPTION:Eptinezumab (Vyepti)\, phase 3\, Migraine.\nStudy: A Study With
  Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine\nEstimated
  primary completion: 26 March 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/eptinezumab-vyepti#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04965675
URL:https://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07191145-10396@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Eptinezumab (Vyepti): Phase 3 readout est. (NCT07191145)
DESCRIPTION:Eptinezumab (Vyepti)\, phase 3.\nStudy: Eary Infusion of Eptine
 zumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)\nEstimat
 ed primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/eptinezumab-vyepti#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07191145
URL:https://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05897320-10396@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20270706
DTEND;VALUE=DATE:20270707
SUMMARY:Eptinezumab (Vyepti): Phase 3 readout est. (NCT05897320)
DESCRIPTION:Eptinezumab (Vyepti)\, phase 3\, Migraine.\nStudy: A Study of E
 ptinezumab in Pediatric Participants With Episodic Migraine\nEstimated pri
 mary completion: 6 July 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/eptinezumab-vyepti#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05897320
URL:https://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07916571-10396@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Eptinezumab (Vyepti): Phase 4 readout est. (NCT07916571)
DESCRIPTION:Eptinezumab (Vyepti)\, phase 4\, Migraine.\nStudy: Migraine Men
 opause Study\nEstimated primary completion: 1 February 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07916571
URL:https://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428838-10396@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Eptinezumab (Vyepti): Phase 3 readout est. (NCT06428838)
DESCRIPTION:Eptinezumab (Vyepti)\, phase 3\, Migraine.\nStudy: Eptinezumab 
 as an Adjunct to Standard of Care for Migraine in an Acute Emergency Conte
 xt\nEstimated primary completion: March 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06428838
URL:https://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05164172-10396@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Eptinezumab (Vyepti): Phase 3 readout est. (NCT05164172)
DESCRIPTION:Eptinezumab (Vyepti)\, phase 3\, Migraine.\nStudy: A Study With
  Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or E
 pisodic Migraine\nEstimated primary completion: 30 April 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05164172
URL:https://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07645833-10396@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Eptinezumab (Vyepti): Phase 3 readout est. (NCT07645833)
DESCRIPTION:Eptinezumab (Vyepti)\, phase 3.\nStudy: Eptinezumab for Chronic
  Headache in Idiopathic Intracranial Hypertension\nEstimated primary compl
 etion: June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ept
 inezumab-vyepti#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07645833
URL:https://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07655440-10396@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Eptinezumab (Vyepti): Phase 4 readout est. (NCT07655440)
DESCRIPTION:Eptinezumab (Vyepti)\, phase 4\, Migraine.\nStudy: Comparing Mi
 graine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patien
 ts With Migraine (COMPACT-PM)\nEstimated primary completion: July 2031. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/eptinezumab-vyepti#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07655440
URL:https://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
